AHK-Cu
DermatologicalAlso known as Alanine-Histidine-Lysine copper, AHK copper
Evidence tier
Limited published literature
15 publications over 26 years · trials not yet curated
- Researched since
- 2000
- Publications
- 15
- Mean purity
- —
- Vendors listing
- 1
No indexed vendor publishes certificate records for AHK-Cu that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2000 — 26 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
15 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is AHK-Cu?
A copper-binding tripeptide (alanine-histidine-lysine) in the copper-peptide class, studied for effects on hair follicles and used as a cosmetic ingredient.
Studied in published research for hair growth and follicle stimulation.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- The effect of tripeptide-copper complex on human hair growth in vitro — Archives of pharmacal research (2007)
Peer-reviewed article indexed in PubMed, published in Archives of pharmacal research (2007).
- Tryptophan and Cysteine Oxidation Products Dominate in α-Lactalbumin-Derived Peptides Analyzed with LC-MS(n) — Journal of food science (2017)
Peer-reviewed article indexed in PubMed, published in Journal of food science (2017).
- X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties — Chemistry (Weinheim an der Bergstrasse, Germany) (2011)
Peer-reviewed article indexed in PubMed, published in Chemistry (Weinheim an der Bergstrasse, Germany) (2011).
- Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death — Stroke (2004)
Peer-reviewed article indexed in PubMed, published in Stroke (2004).
- Copper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses — Shock (Augusta, Ga.) (2003)
Peer-reviewed article indexed in PubMed, published in Shock (Augusta, Ga.) (2003).
- Copper inhibits activated protein C: protective effect of human albumin and an analogue of its high-affinity copper-binding site, d-DAHK — Biochemical and biophysical research communications (2002)
Peer-reviewed article indexed in PubMed, published in Biochemical and biophysical research communications (2002).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| NeuroLabs Research | 78.186% | $0.70 (100%) | 0 | — | — |
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.